Skip to main content
logo
Mirion Technologies, Inc. (MIR)
NYSE: MIR · Real-Time Price · USD
16.62
-0.30 (-1.77%)
Sep 9, 2026, 4:00 PM EDT - Market closed

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Cancer Care Revenue
244.00M237.00M228.10M
Other Medical Revenue
69.70M73.80M71.60M
Total Medical Revenue
313.70M310.80M299.70M
Nuclear Revenue
452.20M374.60M316.60M
Labs and Research Revenue
125.40M122.20M131.70M
Other Nuclear & Safety Revenue
133.60M117.80M112.80M
Total Nuclear & Safety Revenue
711.20M614.60M561.10M
Revenue (Total)
1.02B925.40M860.80M

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
North America Revenue
666.60M582.20M542.20M
Europe Revenue
343.40M327.60M305.60M
Asia Pacific Revenue
14.90M15.60M13.00M
Revenue (Total)
1.02B925.40M860.80M

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Product Revenue
779.80M690.60M643.10M
Service Revenue
245.10M234.80M217.70M
Revenue (Total)
1.02B925.40M860.80M

Adjusted EBITDA

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Adjusted EBITDA
118.80M116.40M104.60M
Nuclear & Safety Adjusted EBITDA
198.40M177.70M159.80M
Corporate & Other Adjusted EBITDA
-67.60M-66.20M-60.80M
Operating Income (Total)
54.50M51.50M24.80M

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Income from Operations
51.90M46.90M22.30M
Nuclear & Safety Income from Operations
107.30M101.10M78.90M
Corporate & Other Income from Operations
-104.70M-96.50M-76.40M
Operating Income (Total)
54.50M51.50M24.80M

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Capital Expenditures
21.20M20.20M27.80M
Nuclear & Safety Capital Expenditures
19.60M18.70M17.70M
Corporate & Other Capital Expenditures
1.70M700.00K3.30M

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Remaining Performance Obligations (RPO)
1.14B1.10B811.90M
Remaining Performance Obligations (RPO) to be Recognized Over NTM
35.00%49.00%54.00%
Order Book
1.20B1.03B843.00M
Medical - Organic Revenue Growth
-3.10%2.60%
Nuclear & Safety - Organic Revenue Growth
-4.40%8.80%
Total Organic Revenue Growth
-3.90%6.60%